Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
暂无分享,去创建一个
G. Sauter | T. Schlomm | S. Steurer | R. Simon | W. Wilczak | S. Minner | M. Tsourlakis | H. Heinzer | M. Graefen | U. Michl | C. Hube-Magg | J. Izbicki | H. Sirma | K. Grupp | Kristina Prien | T. Pham | Thorsten Simon Höhne
[1] J. Korbel,et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.
[2] G. Sauter,et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.
[3] G. Sauter,et al. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence , 2013, Modern Pathology.
[4] G. Sauter,et al. Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers , 2013, International journal of cancer.
[5] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[6] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[7] Lu Wu,et al. Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Chin-Lee Wu,et al. Expression of CD147 is associated with prostate cancer progression , 2012, International journal of cancer.
[9] N. Fineberg,et al. Dual Combination Therapy Targeting DR5 and EMMPRIN in Pancreatic Adenocarcinoma , 2011, Molecular Cancer Therapeutics.
[10] Tim Beißbarth,et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.
[11] Chin-Lee Wu,et al. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.
[12] A. Haese*,et al. The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. , 2011, International journal of oncology.
[13] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[14] R. Reis,et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer , 2011, BMC Cancer.
[15] A. Haese*,et al. High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.
[16] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[17] O. Kallioniemi,et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. , 2010, Cancer research.
[18] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[19] J. Zou,et al. Expression and clinical significance of CD147 in genitourinary carcinomas. , 2010, The Journal of surgical research.
[20] G. Sauter,et al. Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer , 2009, Clinical Cancer Research.
[21] J. Zou,et al. CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer , 2009, Pathology & Oncology Research.
[22] Yang Zhang,et al. [Expression and significance of CD147 protein in prostate cancer]. , 2009, Zhonghua yi xue za zhi.
[23] E. Rosenthal,et al. Anti-EMMPRIN Monoclonal Antibody as a Novel Agent for Therapy of Head and Neck Cancer , 2009, Clinical Cancer Research.
[24] G. Jenster,et al. Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer , 2009, Clinical Cancer Research.
[25] Martin Schostak,et al. Expression and prognostic relevance of annexin A3 in prostate cancer. , 2008, European urology.
[26] G. Sauter,et al. Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients , 2008, Clinical Cancer Research.
[27] A. Haese*,et al. Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.
[28] W. Zhong,et al. CD147, MMP-1, MMP-2 and MMP-9 Protein Expression as Significant Prognostic Factors in Human Prostate Cancer , 2008, Oncology.
[29] B. Trask,et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.
[30] Yong Li,et al. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression , 2008, Cancer Immunology, Immunotherapy.
[31] R. Shah,et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.
[32] A. Haese*,et al. Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.
[33] J. Brooks,et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.
[34] G. Sauter,et al. High incidence of EMMPRIN expression in human tumors , 2006, International journal of cancer.
[35] P. Span,et al. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. , 2006, Cancer letters.
[36] Jing Xu,et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. , 2006, International journal of radiation oncology, biology, physics.
[37] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[38] Yi Tang,et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. , 2005, Cancer research.
[39] M. Urashima,et al. CD147 and matrix metalloproteinase‐2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma , 2004, Cancer.
[40] Rongsong Li,et al. Emmprin Promotes Anchorage-Independent Growth in Human Mammary Carcinoma Cells by Stimulating Hyaluronan Production , 2004, Cancer Research.
[41] Yi Tang,et al. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. , 2004, Molecular cancer research : MCR.
[42] T. Kanekura,et al. Basigin (cd147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts , 2002, International journal of cancer.
[43] K. Pienta,et al. Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.
[44] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[45] Y. Okada,et al. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. , 2000, Cancer letters.
[46] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[47] B. Toole,et al. Stimulation of Matrix Metalloproteinase Production by Recombinant Extracellular Matrix Metalloproteinase Inducer from Transfected Chinese Hamster Ovary Cells* , 1997, The Journal of Biological Chemistry.
[48] H. Moch,et al. Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY , 1996, The Journal of pathology.
[49] H. Guo,et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. , 1995, Cancer research.
[50] G. Sauter,et al. Marked heterogeneity of ERG expression in large primary prostate cancers , 2013, Modern Pathology.
[51] K. Pienta,et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. , 2011, Genome research.
[52] A. Jemal,et al. Global Cancer Statistics , 2011 .